Tregcel is under clinical development by TRACT Therapeutics and currently in Phase I for Kidney Transplant Rejection. According to GlobalData, Phase I drugs for Kidney Transplant Rejection have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tregcel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tregcel overview
Cellular immunotherapy is under development to prevent rejection in living donor kidney transplant recipients and Crohn’s disease. The cells are administered as intravenous infusion. Cell therapy is based on company’s T regulatory cells (Treg) technology.
It was also under development for the treatment of liver transplantation and for the treatment of inflammatory bowel disease including autoimmune hepatitis.
TRACT Therapeutics overview
TRACT Therapeutics., a biotechnology company that developing personalized regulatory T-cell (Treg) therapy. The company is headquartered in United States.
For a complete picture of Tregcel’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
